

Neos Therapeutics, Inc.  
Form 4  
July 28, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**Iannelli Ralph**

(Last) (First) (Middle)

**C/O NEOS THERAPEUTICS, INC., 2940 N. HWY 360**

(Street)

**GRAND PRAIRIE, TX 75050**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**Neos Therapeutics, Inc. [NEOS]**

3. Date of Earliest Transaction (Month/Day/Year)  
**07/28/2015**

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |   |                  |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|---|------------------|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                             |   |                  |
| Common Stock                    | 07/28/2015                           |  | C                              |   | 386,415   | A  | Ⓛ 393,704                         | I | See footnote (2) |
| Common Stock                    | 07/28/2015                           |  | C                              |   | 31,437  | A  | Ⓛ 425,141                         | I | See footnote (2) |
| Common Stock                    | 07/28/2015                           |  | C                              |   | 83,333  | A  | Ⓛ 508,474                         | I | See footnote (3) |
| Common Stock                    | 07/28/2015                           |  | C                              |   | 237,500   | A  | Ⓛ 745,974                         | I | See footnote     |

Edgar Filing: Neos Therapeutics, Inc. - Form 4

|              |            |  |   |        |   |            |         |   |                                       |
|--------------|------------|--|---|--------|---|------------|---------|---|---------------------------------------|
| Common Stock | 07/28/2015 |  | C | 20,833 | A | <u>(1)</u> | 766,807 | I | <u>(2)</u><br>See footnote <u>(3)</u> |
| Common Stock | 07/28/2015 |  | C | 8,333  | A | <u>(1)</u> | 775,140 | I | See footnote <u>(4)</u>               |
| Common Stock | 07/28/2015 |  | C | 56,874 | A | <u>(1)</u> | 832,014 | I | See footnote <u>(2)</u>               |
| Common Stock | 07/28/2015 |  | C | 81,249 | A | <u>(1)</u> | 913,263 | I | See footnote <u>(3)</u>               |
| Common Stock | 07/28/2015 |  | C | 18,332 | A | <u>(1)</u> | 931,595 | I | See footnote <u>(4)</u>               |
| Common Stock | 07/28/2015 |  | C | 2,958  | A | <u>(5)</u> | 934,553 | I | See footnote <u>(3)</u>               |
| Common Stock | 07/28/2015 |  | C | 1,666  | A | <u>(5)</u> | 936,219 | I | See footnote <u>(4)</u>               |
| Common Stock | 07/28/2015 |  | P | 30,000 | A | \$ 15      | 966,219 | I | See footnote <u>(2)</u>               |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |              |                            |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--------------|----------------------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title        | Amount or Number of Shares |
| Series A Preferred                         | <u>(1)</u>   | 07/28/2015                           |  | C                              | 927,397   | <u>(1)</u>   | <u>(1)</u>  | Common Stock | 386,415                    |

Edgar Filing: Neos Therapeutics, Inc. - Form 4

Stock

|  |            |            |   |         |            |            |                          |         |
|--|------------|------------|---|---------|------------|------------|--------------------------|---------|
| Series B Preferred Stock               | <u>(1)</u> | 07/28/2015 | C | 75,450  | <u>(1)</u> | <u>(1)</u> | Common Stock             | 31,437  |
| Series B Preferred Stock               | <u>(1)</u> | 07/28/2015 | C | 200,000 | <u>(1)</u> | <u>(1)</u> | Common Stock             | 83,333  |
| Series B-1 Preferred Stock             | <u>(1)</u> | 07/28/2015 | C | 570,000 | <u>(1)</u> | <u>(1)</u> | Common Stock             | 237,500 |
| Series B-1 Preferred Stock             | <u>(1)</u> | 07/28/2015 | C | 50,000  | <u>(1)</u> | <u>(1)</u> | Common Stock             | 20,833  |
| Series B-1 Preferred Stock             | <u>(1)</u> | 07/28/2015 | C | 20,000  | <u>(1)</u> | <u>(1)</u> | Common Stock             | 8,333   |
| Series C Preferred Stock               | <u>(1)</u> | 07/28/2015 | C | 136,500 | <u>(1)</u> | <u>(1)</u> | Common Stock             | 56,874  |
| Series C Preferred Stock               | <u>(1)</u> | 07/28/2015 | C | 195,000 | <u>(1)</u> | <u>(1)</u> | Common Stock             | 81,942  |
| Series C Preferred Stock               | <u>(1)</u> | 07/28/2015 | C | 44,000  | <u>(1)</u> | <u>(1)</u> | Common Stock             | 18,332  |
| Preferred Stock Warrant (Right to Buy) | <u>(6)</u> | 07/28/2015 | X | 35,500  | <u>(6)</u> | 02/19/2020 | Series C Preferred Stock | 7,100   |
| Preferred Stock Warrant (Right to Buy) | <u>(6)</u> | 07/28/2015 | X | 20,000  | <u>(6)</u> | 02/19/2020 | Series C Preferred Stock | 4,000   |
| Series C Preferred Stock               | <u>(1)</u> | 07/28/2015 | C | 7,100   | <u>(1)</u> | <u>(1)</u> | Common Stock             | 2,958   |
| Series C Preferred Stock               | <u>(1)</u> | 07/28/2015 | C | 4,000   | <u>(1)</u> | <u>(1)</u> | Common Stock             | 1,666   |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| Iannelli Ralph<br>C/O NEOS THERAPEUTICS, INC.<br>2940 N. HWY 360<br>GRAND PRAIRIE, TX 75050     |               | X         |         |       |
| Essex Capital Corp<br>C/O NEOS THERAPEUTICS, INC.<br>2940 N. HWY 360<br>GRAND PRAIRIE, TX 75050 |               | X         |         |       |

## Signatures

/s/ Benjamin Piper,  
attorney-in-fact

07/28/2015

Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- Each share of the Issuer's Series B preferred stock, Series B-1 preferred stock and Series C preferred stock was automatically converted
- (1) on a 2.4-for-1 basis into common stock immediately prior to the closing of the Issuer's initial public offering. The shares of Series B preferred stock and Series C preferred stock had no expiration date.
  - (2) The security listed in column 1 is held directly by Essex Capital Corporation ("Essex"), of which Ralph Iannelli is the sole stockholder. The security listed in column 1 is held directly by KF Investment Partners, LP ("KF"). Essex is the 50% limited partner of KF, and Ralph Iannelli is the General Partner of KF and may be deemed to have voting and dispositive power with respect to such shares. Each Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein.
  - (3) The security listed in column 1 is held directly in the name of SIU Capital LLC ("SIU"). Essex is the 50% limited partner of SIU, and Ralph Iannelli is the Managing Member of SIU, and may be deemed to have voting and dispositive power with respect to such shares. Each Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein.
  - (4) Based upon and including the number of shares of common stock listed in column 4 issued upon the automatic conversion of the underlying shares of Series C preferred stock in accordance with Footnote (1) above, such shares of Series C preferred stock issued in accordance with the Cashless Exercise Provision set forth in Footnote (6) below.
  - (5) The preferred stock warrant was automatically exercised immediately prior to the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision pursuant to which the holder receives a net number of shares of Series C preferred stock based on the fair market value of such stock at the time of exercise, after deducting the aggregate exercise price (the "Cashless Exercise Provision"). The shares of Series C preferred stock have no expiration date.
  - (6)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.